Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) updated its FY17 earnings guidance on Monday. The company provided EPS guidance of $1.35-1.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.71. The company issued revenue guidance of $220-230 million, compared to the consensus revenue estimate of $227.27 million.Sucampo Pharmaceuticals also updated its FY16 guidance to $1.20-1.25 EPS.
Several brokerages recently issued reports on SCMP. Jefferies Group restated a hold rating and issued a $16.00 price objective (up from $14.00) on shares of Sucampo Pharmaceuticals in a report on Friday, November 11th. Vetr lowered shares of Sucampo Pharmaceuticals from a strong-buy rating to a buy rating and set a $14.00 price objective on the stock. in a report on Monday, September 19th. Mizuho upgraded shares of Sucampo Pharmaceuticals from a neutral rating to a buy rating and set a $16.00 price target on the stock in a research note on Thursday, December 22nd. Finally, Maxim Group boosted their price target on shares of Sucampo Pharmaceuticals from $17.00 to $19.00 and gave the stock a buy rating in a research note on Tuesday, November 15th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $17.33.
Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) traded up 0.74% during trading on Monday, hitting $13.55. The stock had a trading volume of 757,693 shares. Sucampo Pharmaceuticals, Inc. has a one year low of $9.59 and a one year high of $17.55. The company has a market cap of $580.18 million, a P/E ratio of 45.78 and a beta of 1.72. The stock’s 50-day moving average price is $14.93 and its 200-day moving average price is $12.77.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. The business had revenue of $57.90 million for the quarter, compared to analyst estimates of $51.30 million. Sucampo Pharmaceuticals had a return on equity of 44.19% and a net margin of 6.29%. The business’s revenue for the quarter was up 73.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 earnings per share. On average, equities research analysts forecast that Sucampo Pharmaceuticals, Inc. will post $1.22 EPS for the current fiscal year.
In other news, CEO Peter Greenleaf sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, November 29th. The stock was sold at an average price of $16.84, for a total value of $3,368,000.00. Following the transaction, the chief executive officer now directly owns 120,054 shares in the company, valued at approximately $2,021,709.36. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew P. Smith sold 1,766 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $15.58, for a total value of $27,514.28. Following the completion of the transaction, the chief financial officer now owns 348 shares in the company, valued at $5,421.84. The disclosure for this sale can be found here. 3.31% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the propert of of Community Financial News. If you are reading this article on another website, it was copied illegally and republished in violation of United States & international trademark and copyright legislation. The correct version of this article can be accessed at https://www.com-unik.info/2017/01/09/sucampo-pharmaceuticals-inc-scmp-issues-fy17-earnings-guidance.html.
Several institutional investors have recently added to or reduced their stakes in SCMP. Zacks Investment Management purchased a new position in Sucampo Pharmaceuticals during the second quarter worth approximately $110,000. Price T Rowe Associates Inc. MD purchased a new position in Sucampo Pharmaceuticals during the third quarter worth approximately $129,000. UBS Asset Management Americas Inc. purchased a new position in Sucampo Pharmaceuticals during the second quarter worth approximately $144,000. Raymond James & Associates increased its position in Sucampo Pharmaceuticals by 12.0% in the second quarter. Raymond James & Associates now owns 16,603 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 1,781 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in Sucampo Pharmaceuticals during the third quarter worth approximately $215,000. Institutional investors own 41.03% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
What are top analysts saying about Sucampo Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sucampo Pharmaceuticals Inc. and related companies.